Characterization of Clinical Isolates ofKlebsiella pneumoniae from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum β-Lactamase Detection Methods

ABSTRACT Extended-spectrum β-lactamases (ESBLs) are enzymes found in gram-negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. In 1999, the National Committee for Clinical Laboratory Standards (NCCLS) published methods for screening and confirming the presence of ESBLs in Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli. To evaluate the confirmation protocol, we tested 139 isolates of K. pneumoniae that were sent to Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) from 19 hospitals in 11 U.S. states. Each isolate met the NCCLS screening criteria for potential ESBL producers (ceftazidime [CAZ] or cefotaxime [CTX] MICs were ≥2 μg/ml for all isolates). Initially, 117 (84%) isolates demonstrated a clavulanic acid (CA) effect by disk diffusion (i.e., an increase in CAZ or CTX zone diameters of ≥5 mm in the presence of CA), and 114 (82%) demonstrated a CA effect by broth microdilution (reduction of CAZ or CTX MICs by ≥3 dilutions). For five isolates, a CA effect could not be determined initially by broth microdilution because of off-scale CAZ results. However, a CA effect was observed in two of these isolates by testing cefepime and cefepime plus CA. The cefoxitin MICs for 23 isolates that failed to show a CA effect by broth microdilution were ≥32 μg/ml, suggesting either the presence of an AmpC-type β-lactamase or porin changes that could mask a CA effect. By isoelectric focusing (IEF), 7 of the 23 isolates contained a β-lactamase with a pI of ≥8.3 suggestive of an AmpC-type β-lactamase; 6 of the 7 isolates were shown by PCR to contain bothampC-type and blaOXA genes. The IEF profiles of the remaining 16 isolates showed a variety of β-lactamase bands, all of which had pIs of ≤7.5. All 16 isolates were negative by PCR with multiple primer sets for ampC-type,blaOXA, and blaCTX-Mgenes. In summary, 83.5% of the K. pneumoniae isolates that were identified initially as presumptive ESBL producers were positive for a CA effect, while 5.0% contained β-lactamases that likely masked the CA effect. The remaining 11.5% of the isolates studied contained β-lactamases that did not demonstrate a CA effect. An algorithm based on phenotypic analyses is suggested for evaluation of such isolates.

[1]  K. Kaye,et al.  Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. , 2004, Infectious disease clinics of North America.

[2]  P. Nordmann,et al.  Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. , 2001, The Journal of antimicrobial chemotherapy.

[3]  P. Nordmann,et al.  OXA-28, an Extended-Spectrum Variant of OXA-10 β-Lactamase from Pseudomonas aeruginosa and Its Plasmid- and Integron-Located Gene , 2001, Antimicrobial Agents and Chemotherapy.

[4]  A. Oliver,et al.  Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing β-Lactamase (CTX-M-10) Isolated in Spain , 2001, Antimicrobial Agents and Chemotherapy.

[5]  P. Nordmann,et al.  Plasmid-Mediated Cephalosporinase ACC-1 in Clinical Isolates of Proteus mirabilis and Escherichia coli , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[6]  A. Oliver,et al.  Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated β-Lactamase from an Escherichia coli Strain Isolated in Spain , 2000, Antimicrobial Agents and Chemotherapy.

[7]  K. Kaye,et al.  PATHOGENS RESISTANT TO ANTIMICROBIAL AGENTS , 2000 .

[8]  P. Coudron,et al.  Occurrence and Detection of AmpC Beta-Lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates at a Veterans Medical Center , 2000, Journal of Clinical Microbiology.

[9]  L. Tzouvelekis,et al.  CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes , 2000 .

[10]  L. Rice,et al.  High-Level Expression of Chromosomally Encoded SHV-1 β-Lactamase and an Outer Membrane Protein Change Confer Resistance to Ceftazidime and Piperacillin- Tazobactam in a Clinical Isolate of Klebsiella pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.

[11]  P. Nordmann,et al.  OXA-type beta-lactamases. , 1999, Current pharmaceutical design.

[12]  R. Gaynes,et al.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Jacoby,et al.  Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[14]  L. Rice,et al.  Inhibitor resistant class A beta-lactamases. , 1999, Frontiers in bioscience : a journal and virtual library.

[15]  G. Paul,et al.  Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. , 1999, The Journal of antimicrobial chemotherapy.

[16]  P. Nordmann,et al.  Trends in β-Lactam Resistance Among Enterobacteriaceae , 1998 .

[17]  L. Martínez-Martínez,et al.  Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae Isolates from Clinical Samples and Activities of Cephalosporins and Carbapenems , 1998, Antimicrobial Agents and Chemotherapy.

[18]  L. Bret,et al.  Chromosomally Encoded AmpC-Type β-Lactamase in a Clinical Isolate of Proteus mirabilis , 1998, Antimicrobial Agents and Chemotherapy.

[19]  G. French,et al.  Mechanism and stability of hyperproduction of the extended-spectrum beta-lactamase SHV-5 in Klebsiella pneumoniae. , 1997, The Journal of antimicrobial chemotherapy.

[20]  P. Nordmann,et al.  OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta-lactamase from Pseudomonas aeruginosa , 1997, Antimicrobial agents and chemotherapy.

[21]  F. Kayser,et al.  Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12 , 1997, Antimicrobial agents and chemotherapy.

[22]  M. Gazouli,et al.  Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant , 1997, Antimicrobial agents and chemotherapy.

[23]  A. Medeiros,et al.  Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia , 1997, Antimicrobial agents and chemotherapy.

[24]  R. Gaynes,et al.  Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  G L French,et al.  Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase , 1996, Journal of clinical microbiology.

[26]  G. Jacoby,et al.  In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins , 1996, Antimicrobial agents and chemotherapy.

[27]  I. Stemplinger,et al.  Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases , 1996, Antimicrobial agents and chemotherapy.

[28]  Sanders Cc In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. , 1996 .

[29]  D. Livermore beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[30]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[31]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[32]  S. B. Singer,et al.  Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. , 1989, The Journal of antimicrobial chemotherapy.

[33]  J. Frère,et al.  Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products. , 1988, The Biochemical journal.

[34]  P Huovinen,et al.  Sequence of PSE-2 beta-lactamase , 1988, Antimicrobial Agents and Chemotherapy.

[35]  P. H. Roy,et al.  Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Normark,et al.  Sequence of the Citrobacter freundii OS60 chromosomal ampCβ‐lactamase gene , 1986 .

[37]  J. W. Dale,et al.  Sequence of the OXA2 β‐lactamase: comparison with other penicillin‐reactive enzymes , 1985, FEBS letters.

[38]  T. Grundström,et al.  ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[40]  A. Harris,et al.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases. , 1975, Journal of general microbiology.

[41]  M J Ferraro Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[42]  David M. Livermore,et al.  b-Lactamases in Laboratory and Clinical Resistance , 1995 .

[43]  D. Persing,et al.  Diagnostic molecular microbiology : principles and applications , 1993 .